Lai Jennifer C, Shui Amy M, Molinari Michele, Rahimi Robert S, Ladner Daniela P, Ganger Daniel R, Kappus Matthew, King Elizabeth A, Tevar Amit D, Volk Michael L, Duarte-Rojo Andres, Verna Elizabeth C
Department of Medicine, University of California, San Francisco, USA.
Department of Surgery and Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Hepatology. 2025 Mar 25. doi: 10.1097/HEP.0000000000001320.
Frailty is strongly associated with mortality after liver transplantation. However, national guidelines discourage its use as a sole reason to decline a patient for liver transplantation, as some frail patients have acceptable outcomes. We aimed to develop a composite index, the Liver Transplant Comorbidity Index (LTCI), integrating frailty and other comorbidities, as a risk factor for longer-term (3-year) posttransplant mortality.
This 8-center prospective Functional Assessment in Liver Transplantation (FrAILT) Study included adult recipients of a primary deceased donor liver transplant from 2012 to 2022. Frailty was measured using the Liver Frailty Index (LFI ≥4.5=frail). Other candidate variables included demographics, laboratories, and comorbidities. Cox proportional hazards regression with best subset selection was used to identify risk factors of 3-year posttransplant death. The final model was selected based on Akaike Information Criterion and clinical pragmatism. Of 1472 liver transplant recipients, 290 (20%) were frail. Three-year posttransplant mortality was higher in frail versus non-frail patients (13% vs. 8%; p =0.03). The final LTCI included 5 variables: frailty, coronary artery disease, HCC, renal dysfunction, and diabetes. Three-year posttransplant mortality in low-risk, moderate-risk, and high-risk LTCI groups was 93%, 87%, and 80%, respectively. In multivariable analysis, after adjusting for donor factors (age and donation after circulatory death), both moderate-risk (HR: 2.23, 95% CI: 1.46-3.40; p <0.001) and high-risk (HR: 2.78, 95% CI: 1.67-4.64; p <0.001) status were associated with 3-year posttransplant mortality.
The LTCI, comprising 5 pretransplant clinical parameters, effectively identifies patients at increased risk of posttransplant mortality. By integrating frailty in the context of other comorbidities, the LTCI can help providers better weigh the relative transplant risks and benefits and standardize the selection of transplant candidates.
衰弱与肝移植后的死亡率密切相关。然而,国家指南不鼓励将其作为拒绝患者进行肝移植的唯一理由,因为一些衰弱患者也能取得可接受的预后。我们旨在开发一种综合指数,即肝移植合并症指数(LTCI),将衰弱与其他合并症整合起来,作为移植后长期(3年)死亡率的风险因素。
这项8中心前瞻性肝移植功能评估(FrAILT)研究纳入了2012年至2022年接受原发性脑死亡供体肝移植的成年受者。使用肝衰弱指数(LFI≥4.5为衰弱)来衡量衰弱程度。其他候选变量包括人口统计学、实验室检查结果和合并症。采用最佳子集选择的Cox比例风险回归来确定移植后3年死亡的风险因素。最终模型基于赤池信息准则和临床实用性进行选择。在1472例肝移植受者中,290例(20%)为衰弱患者。衰弱患者移植后3年死亡率高于非衰弱患者(13%对8%;p=0.03)。最终的LTCI包括5个变量:衰弱、冠状动脉疾病、肝癌、肾功能不全和糖尿病。低风险、中风险和高风险LTCI组移植后3年死亡率分别为93%、87%和80%。在多变量分析中,在调整供体因素(年龄和循环死亡后捐赠)后,中风险(HR:2.23,95%CI:1.46 - 3.40;p<0.001)和高风险(HR:2.78,95%CI:1.67 - 4.64;p<0.001)状态均与移植后3年死亡率相关。
包含5个移植前临床参数的LTCI能有效识别移植后死亡风险增加的患者。通过在其他合并症背景下整合衰弱因素,LTCI可帮助医疗人员更好地权衡相对的移植风险和益处,并规范移植候选者的选择。